Blue Jet Healthcare OFS Opens September 10, Floor Price at ₹675

Disclaimer This is an AI-assisted live blog with updates sourced from multiple news outlets and agencies Disclaimer

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

live

• bselive
• nselive

Volume

Todays L/H

More

×

Blue Jet Healthcare's offer for sale (OFS) will open on September 10, 2025, for non-retail investors and on September 11, 2025, for retail investors. The sale is being conducted by promoter Akshay Bansarilal Arora to meet minimum public shareholding requirements.

The OFS will offer up to 5,925,925 equity shares, representing 3.42% of the total issued and paid-up equity share capital of the company, with an option to additionally sell 5,925,925 equity shares, representing another 3.42% of the equity share capital. If the oversubscription option is exercised, the total offer size will represent 6.83% of the company's equity share capital.

The floor price for the OFS is set at ₹675 per equity share.

Offer Details

Allocation Methodology

• Minimum 25% of the offer shares will be reserved for mutual funds and insurance companies, subject to valid bids at or above the floor price.
• Minimum 10% of the offer shares will be reserved for allocation to retail investors.
• No single bidder, other than mutual funds and insurance companies, will be allocated more than 25% of the offer shares.
• Retail investors can bid at or above the floor price or at a cut-off price.

Other Key Points

• The seller reserves the right to either conclude the offer to the extent of the order placed or cancel the offer in full.
• The offer may be cancelled by the seller if there is insufficient demand from non-retail investors at or above the floor price.
• ICICI Securities Limited, Kotak Securities Limited, Motilal Oswal Financial Services Limited, and Nomura Financial Advisory and Securities (India) Private Limited are the brokers for the offer.

This offer is being undertaken by the Sellers for achieving the public shareholding in the Company, as prescribed under the first proviso to the Rule 19A(5) of the Securities Contracts (Regulation) Rules, 1957 and Regulation 38 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.